Acute and Subchronic Toxicity Profile of Withania somnifera Root Extract in a Rat Model

Authors

  • Fernandez D Department of Pharmacognosy, University of Salamanca, Salamanca, Spain Author
  • Marchand M Department of Toxicology, Sorbonne University, Paris, France Author
  • Visser F Department of Pharmacology, Erasmus University Rotterdam, Rotterdam, Netherlands Author

DOI:

https://doi.org/10.5281/zenodo.22664545

Keywords:

Withania somnifera, ashwagandha, acute oral toxicity, subchronic toxicity, NOAEL

Abstract

Background: Withania somnifera (ashwagandha) root extract is widely used as a stress-reducing and adaptogenic supplement,
and clinical trials have generally reported favorable tolerability. However, sporadic case reports and case series describe hepatic
and thyroid-related adverse events associated with its use, creating a gap between reassuring trial-level safety data and isolated
post-marketing signals.
Objective: To characterize the acute and subchronic oral toxicity of a standardized hydroalcoholic Withania somnifera root extract
in rats, with particular attention to hepatic and thyroid endpoints, and to determine a no-observed-adverse-effect level (NOAEL).
Methods: Acute oral toxicity was assessed in female Wistar rats using a limit-dose protocol modeled on OECD Test Guideline 423 (up
to 5000 mg/kg). Subchronic toxicity was assessed in male and female rats dosed once daily by gavage at 250, 500, or 1000
mg/kg/day for 28 days, with a 90-day extension informed by OECD 407/408 principles, evaluating body weight, hematology,
clinical chemistry, thyroid hormones, organ weights, and histopathology.
Results: No mortality occurred at the acute limit dose (LD50 > 5000 mg/kg; GHS Category 5/unclassified). In the subchronic phase,
1000 mg/kg/day produced mild, transient elevation of serum ALT, minimal centrilobular hepatocyte hypertrophy, and a modest
reduction in total T4 with compensatory TSH rise at day 28, all of which attenuated by day 90 despite continued dosing. No adverse
findings occurred at 250 or 500 mg/kg/day, yielding a 28-day NOAEL of 500 mg/kg/day.
Conclusion: This extract showed a wide margin of safety relative to typical human supplement dosing, consistent with prior
preclinical and clinical reports. The mild, reversible hepatic and thyroid changes observed only at the highest dose offer a plausible,
though partial, biological context for the rare idiosyncratic liver and thyroid signals reported clinically, supporting continued
monitoring in vulnerable populations.

References

Bashir A, Nabi M, Tabassum N, Afzal S, Ayoub M (2023) An updated review on phytochemistry and molecular targets of Withania somnifera (L.) Dunal (Ashwagandha). Frontiers in Pharmacology, 14:1049334, DOI:10.3389/fphar.2023.1049334.

Mikulska P, Malinowska M, Ignacyk M, Szustowski P, Nowak J, Pesta K, Szelag M, Szklanny D, Judasz E, Kaczmarek G, Ejiohuo OP, Paczkowska-Walendowska M, Gosciniak A, Cielecka-Piontek J (2023) Ashwagandha (Withania somnifera)-Current Research on the Health-Promoting Activities: A Narrative Review. Pharmaceutics, 15(4):1057, DOI:10.3390/pharmaceutics15041057.

Sharifi-Rad M, Tayeboon GS, Niknam F, Iriti M, Sharifi-Rad J, Ezzat SM, Sharifi-Rad M, Salehi B, Yousaf Z, Iriti M, Martins N (2021) Chemical Composition, Biological Activity, and Health-Promoting Effects of Withania somnifera for Pharma-Food Industry Applications. Journal of Food Quality, 2021:8985179, DOI:10.1155/2021/8985179.

Chandrasekhar K, Kapoor J, Anishetty S (2012) A Prospective, Randomized Double-Blind, Placebo-Controlled Study of Safety and Efficacy of a High-Concentration Full-Spectrum Extract of Ashwagandha Root in Reducing Stress and Anxiety in Adults. Indian Journal of Psychological Medicine, 34(3):255-262, DOI:10.4103/0253-7176.106022.

Vaidya VG, Gothwad A, Ganu G, Girme A, Modi SJ, Hingorani L (2024) Clinical safety and tolerability evaluation of Withania somnifera (L.) Dunal (Ashwagandha) root extract in healthy human volunteers. Journal of Ayurveda and Integrative Medicine, 15(1):100859, DOI:10.1016/j.jaim.2023.100859.

Toth M, Benedek AE, Longerich T, Seitz HK (2023) Ashwagandha-induced acute liver injury: A case report. Clinical Case Reports, 11(3):e7078, DOI:10.1002/ccr3.7078.

Philips CA, Valsan A, Theruvath AH, Ravindran R, Oommen TT, Rajesh S, Bishnu S, Augustine P (2023) Ashwagandha-induced liver injury - a case series from India and literature review. Hepatology Communications, 7(10):e0270, DOI:10.1097/HC9.0000000000000270.

Panda S, Kar A (1998) Changes in thyroid hormone concentrations after administration of ashwagandha root extract to adult male mice. Journal of Pharmacy and Pharmacology, 50(9):1065-1068, DOI:10.1111/j.2042-7158.1998.tb06923.x.

Gannon JM, Forrest PE, Roy Chengappa KN (2014) Subtle changes in thyroid indices during a placebo-controlled study of an extract of Withania somnifera in persons with bipolar disorder. Journal of Ayurveda and Integrative Medicine, 5(4):241-245, DOI:10.4103/0975-9476.146566.

Prabu PC, Panchapakesan S (2012) Acute and sub-acute oral toxicity assessment of the hydroalcoholic extract of Withania somnifera roots in Wistar rats. Phytotherapy Research, 26(9):1268-1272, DOI:10.1002/ptr.4854.

Balkrishna A, Sinha S, Srivastava J, Varshney A (2022) Withania somnifera (L.) Dunal whole-plant extract demonstrates acceptable non-clinical safety in rat 28-day subacute toxicity evaluation under GLP-compliance. Scientific Reports, 12(1):11047, DOI:10.1038/s41598-022-14944-x.

Wangikar P, Chaudhari P, Sharma E, Godse C, Vora A, Nair S (2024) Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats. Drug Metabolism and Personalized Therapy, 39, DOI:10.1515/dmdi-2024-0056.

Langade D, Kalaiselvan P, Gayathri V, Siva R (2023) Ninety-day repeated dose toxicity of Ashwagandha (Withania somnifera) root extract in Wistar rats. Toxicology Reports, 11:189-199, DOI:10.1016/j.toxrep.2023.07.010.

Jitareanu A, Trifan A, Vieriu M, Caba IC, Martu I, Agoroaei L (2023) Current Trends in Toxicity Assessment of Herbal Medicines: A Narrative Review. Processes, 11(1):83, DOI:10.3390/pr11010083.

OECD (2001) Test No. 423: Acute Oral Toxicity - Acute Toxic Class Method. OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, DOI:10.1787/9789264071001-en.

OECD (2008) Test No. 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents. OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, DOI:10.1787/9789264070684-en.

OECD (2018) Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents. OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, DOI:10.1787/9789264070707-en.

United Nations Economic Commission for Europe (2019) Globally Harmonized System of Classification and Labelling of Chemicals (GHS), Eighth Revised Edition. United Nations, New York and Geneva, DOI:10.18356/9789210043336.

Gupta SK, Jadhav S, Gohil D, Panigrahi GC, Kaushal RK, Gandhi K, Patil A, Chavan P, Gota V (2022) Safety, toxicity and pharmacokinetic assessment of oral Withaferin-A in mice. Toxicology Reports, 9:1204-1212, DOI:10.1016/j.toxrep.2022.09.010.

Madireddy R, Dodda S, Chinta G, Alluri KV (2026) Toxicological Assessment of LN20188, a Botanical Combination of Withania somnifera Root and Abelmoschus esculentus Fruit Extracts. BioMed Research International, 2026:6355273, DOI:10.1155/bmri/6355273.

Kalaivani P, Siva R, Gayathri V, Langade D (2024) Mutagenicity and safety evaluation of Ashwagandha (Withania somnifera) root aqueous extract in different models. Toxicology Reports, 12:41-47, DOI:10.1016/j.toxrep.2023.12.005.

Kalaiselvan K, Sweatha V, Gayathri V, Kalaivani P, Siva R, Tamrakar S (2025) Reproductive and developmental safety assessment of Ashwagandha (Withania somnifera) root extract in Wistar rats. Frontiers in Pharmacology, 16:1572025, DOI:10.3389/fphar.2025.1572025.

Downloads

Published

2025-06-17